Dr. Diego de Miguel Perez is a postdoctoral researcher at the Genyo Center in Spain and an adjunct faculty at The Ohio State University Wexner Medical Center, USA. His work focuses on identifying liquid biopsy biomarkers to predict and understand the mechanisms of tumor progression and treatment resistance in lung cancer. His research has helped advance the study of liquid biopsies, mainly circulating tumor cells and extracellular vesicles, as a minimally invasive tool with the aim of clinical implementation to ultimately improve the lives of patients with lung cancer and other malignancies.

Roberto Borea, MD, is a Research Assistant Professor at The Ohio State University Comprehensive Cancer Center, within the Department of Internal Medicine, Division of Medical Oncology. He is also an active member and Chair of the Young Committee of the International Society of Liquid Biopsy (ISLB), contributing to the strategic development of the Society’s scientific and educational initiatives. At The Ohio State University, Dr. Borea works in Professor Christian Rolfo’s laboratory, where his research is firmly positioned at the interface between clinical oncology and translational science. His work focuses on the integration of liquid biopsy technologies into routine clinical practice, with particular emphasis on lung cancer. By leveraging circulating tumor DNA (ctDNA) and extracellular vesicle–based analyses, his research aims to refine treatment monitoring, identify early mechanisms of resistance, and ultimately support more precise and dynamic therapeutic decision-making. In short, he operates where bench meets bedside, without losing sight of real-world clinical impact. 

Dr. Borea obtained his Medical Degree magna cum laude and completed his residency in Medical Oncology at the University of Genoa, where he is currently pursuing a PhD focused on translational research. Moreover, he previously completed an 18-month research fellowship at the University of North Carolina at Chapel Hill under the guidance of Professor Gianpietro Dotti, where he worked on the development of innovative CAR-T cell strategies in both hematologic and solid tumors. A key milestone in his scientific development was his subsequent advanced training in molecular biology at the University of Naples, under the mentorship of Professor Umberto Malapelle, which further strengthened his expertise in biomarker development and molecular diagnostics. Dr. Borea has authored numerous peer-reviewed publications and regularly presents his research at major international congresses, including ASCO, ESMO, and the World Conference on Lung Cancer. His contributions have been recognized through several competitive awards and grants. Through his academic, translational, and organizational roles, he remains committed to advancing non-invasive precision oncology and shaping the future of liquid biopsy in clinical cancer care.

Edgardo S. Santos Castillero, MD, FACP, FASCO practices at The Oncology Institute (TOI) of Hope and Innovation and is Clinical Associate Professor at Charles E. Schmidt College of
Medicine/Florida Atlantic University. Dr. Santos is the Medical Director at Broward County,
Florida for TOI, the Lead Physician for TOI Lung Cancer Center of Excellence and the President of Florida Society of Clinical Oncology (FLASCO). He is also an active member of the Membership Committee as well as Editorial Group member IASLC Lung Cancer News (ILCN) of the International Association for the Study of Lung Cancer (IASLC), member of the Evidence-based Medicine Committee, Head and Neck Guideline Advisory Group and member of the 2023, 2024 and 2025 ASCO-SEP Item Writing Task Force for the American Society of Clinical Oncology (ASCO). Dr. Santos earned his M.D. in 1994 at the University of Panama, School of Medicine, Republic of Panama. He completed his internship and residency training in Internal Medicine at Jackson Memorial Medical Center, University of Miami School of Medicine. Then, he went on to complete his fellowship in Hematology/Oncology at the Sylvester Comprehensive Cancer Center, Miami, Florida. He was selected “Best Fellow” in Hematology/Oncology Division as well as the Department of Medicine in 2003 and was a recipient of “The Spirit Award” by the American Cancer Society. Dr. Santos has authored or co-authored more than 100 manuscripts in peer-reviewed journals and serves as reviewer for several scientific publications. His focus and expertise in on lung cancer diagnosis, management, and research.

Dr. Santos is a former faculty member of University of Miami Miller School of Medicine, Miami,
Florida where he held an academic rank as an Associate Professor of Medicine (2008-2012) and
Tulane University Health Sciences Center, New Orleans, Louisiana (2004-2008). Dr. Santos has
occupied several administrative, educational, and research leadership positions including Tulane
University Principal Investigator at Southwest Oncology Group (SWOG), Associate Scientific
Director of Tulane Cancer Center’s Office of Clinical Research, Associate Director of the
Fellowship Programs (Tulane University and University of Miami), Chief of the
Hematology/Oncology Section at the Southeast Louisiana Veterans Healthcare System, Chair of
the Committee Research Advisory Board, Co-Leader of Clinical Research for the Louisiana Cancer
Research Consortium, Co-Leader of the Head and Neck Cancer Program at Sylvester Cancer
Center, Medical Director of Cancer Research at Lynn Cancer Institute/Boca Raton Regional
Hospital, Medical Director of Research Services at Florida Precision Oncology/Genesis Care US
and member of the Global Lung Cancer Committee/Genesis Care, among others. He is an active
member of ACP, ASCO, ASH, AACR, ESMO, IASLC, OLA, and ILBS

Dr. Aya El Helali is a clinician scientist specializing in early-phase clinical trials, drug
development, biomarker discovery, and genomics, with focused expertise in neurooncology. She is a tenure-track Clinical Assistant Professor in the Department of Clinical
Oncology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of
Hong Kong. She serves as Co-Chair of the HKU-Hong Kong Sanatorium & Hospital
Molecular Tumor Board and leads the Primary and Recurrent CNS Tumor Research
Program. Her work bridges translational science and clinical implementation, with a strong
emphasis on precision oncology, including the development of liquid biopsy approaches
using blood and cerebrospinal fluid for molecular profiling and treatment monitoring.

Dr. El Helali holds active leadership roles in the neuro-oncology community. She is the First
Vice President and Past President of the Hong Kong Neuro-Oncology Society, a Committee
Member of the ESMO Precision Oncology Task Force, and an ESMO Faculty Member for the
CNS Tumours Faculty Group. She also serves as an Advisor to the Greater Bay Area
International Clinical Trials Institute, contributing to the strategic development of
innovative neuro-oncology clinical trial infrastructure.

She obtained her medical degree from the National University of Ireland, Galway,
graduating with honors and receiving gold medals in Medicine and Surgery. She completed
her PhD at Queen’s University Belfast as a Sir Allen McClay Clinical Research Fellow,
focusing on biomarker discovery and early drug development, followed by postdoctoral
work advancing novel immunotherapeutic combination strategies.

Her translational research program focuses on mechanisms of resistance to immune
checkpoint inhibitors, including immune escape, epigenetic regulation, metabolomic
reprogramming, and liquid biopsy-driven precision oncology in CNS tumors. Her work has
been recognized with multiple awards, including the HKU Faculty Outstanding Research
Output Award (2024, 2025) and the HKU/HKWC Clinical Service of Excellence Award
(2025)

Prof. Nicola Fusco is Head of the Division of Pathology and Somatic Molecular Diagnostics at the European Institute of Oncology in Milan and Professor of Pathology at the University of Milan. An internationally recognized leader in molecular pathology and pioneer in applying AI to digital pathology, he leads a team focused on innovation in diagnostics and applied research, with clinical expertise in solid tumors, particularly breast cancer. Prof. Fusco co-chairs the Quality Control & Accreditations Committee of the International Society of Liquid Biopsy (ISLB), coordinates the Liquid Biopsy Task Force of the Italian Molecular Pathology and Precision Medicine Group (PMMP-SIAPeC), and serves on the Multidisciplinary Scientific Council of the European School of Oncology (ESO). He has addressed the Italian Senate and Chamber of Deputies on AI in healthcare and contributed to national and international guidelines in breast cancer, molecular pathology, and liquid biopsy. His achievements have been recognized with major international awards, competitive research grants—including ERC Synergy and PNRR FAIR–Adaptive AI for Digital Health—and listings among the world’s Top 2% Scientists in 2023, 2024, and 2025 according to Stanford University.

Dr. Valeria Denninghoff is an internationally recognized leader in Molecular Pathology and Precision Medicine, with a strong focus on next-generation sequencing (NGS) and translational oncology. In 1999, she established Argentina’s first Molecular Pathology laboratory, becoming a regional pioneer in molecular diagnostics and clinical platform development. Over more than two decades at CEMIC (1999–2020), she led the section and built a comprehensive high-complexity program, strengthening Molecular Pathology, Molecular Oncology, Molecular Onco-Hematology, and Molecular Gyneco-Oncology.

She also co-founded the Tumor Bank (2008) and spearheaded the implementation of sequencing technologies—from Sanger to NGS—across both research and routine clinical care. Since November 2020, she has served as Director of the UBA–CONICET Molecular Clinical Laboratory, bridging academic excellence, clinical impact, and scientific leadership. Her international profile is further reinforced by her ongoing work in Spain at the Department of Pathology, San Cecilio University Clinical Hospital–ibs.GRANADA, and within the Liquid Biopsy and Cancer Interception group at GENYO (Centre for Genomics and Oncological Research; Pfizer/University of Granada/Andalusian Regional Government). She holds prominent roles in global scientific societies, including membership in the IASLC Pathology Committee’s Molecular Working Group (2023–2027) and Chair of the ISLB Membership Committee (2025–2029). Her international training includes rotations and fellowships at MD Anderson Cancer Center (Houston, USA), Kindai University (Japan), A.C. Camargo Cancer Center (Brazil), and Centre René Huguenin/INSERM (France), underpinning an extensive global collaborative network. She earned her PhD from the University of Buenos Aires (2006) and holds formal specialties in Genetics (Molecular Genetics/Human Genetics) and Clinical Biochemistry–Genetics (2024), with demonstrated expertise in melanoma and in colorectal, lung, and pancreatic cancers.

Paul Hofman, MD, PhD, is Professor in Pathology at the University Côte d’Azur (Nice, France) since 1995. He went in different institutions for his postdoctoral training, at the Brigham and Women’s Hospital (Harvard University, Boston) and at the Max Planck Institute (Tubingen, Germany). Then, he was the Head of the Laboratory of Clinical and Experimental Pathology at Louis Pasteur Hospital in Nice, France, from 2004 to 2025. He is currently the Head of the Inserm U1081 laboratory at the Nice Côte d’Azur University. His career exemplifies the integration of basic science, translational research, and clinical applications to benefit lung cancer patients. From bench to bedside and back to bench, he has consistently developed innovative diagnostic approaches in thoracic oncology. He developed integrative pathology concept from both tissue and liquid biopsies thanks to digital pathology, molecular biology, computational pathology activities, multi-omics in order to setup an holistic approach of lung diseases, from inflammatory processes, to senescent, preneoplastic and tumor cell proliferation.

Moreover, he was the Director of the PhD Program at Nice Sophia Antipolis University and he is the Director of the International MSc Biobanks and Complex Data Management since 2018. Since 2023, he is the Director of a new Institute dedicated to Respiratory Diseases, the IHU RespirRERA (www.ihu-respirera.fr). This IHU RespirERA aims to be the only Center of Excellence at the Nationa Level in France for Respiratory Diseases care, research and innovative development programs and international educational training in thoracic pathology and pulmonology. Paul Hofman is member of the Royal Academia of Medicine in Belgium and he received different awards such as the Gold Medal of Nice City, and the Shields Warren Medal (Harvard Medical School). He was the Chair of the Pulmonary Pathology Working Group at the European Society of Pathology from 2021 to 2024 and he is currently the Chair of the Molecular Pathology Working Group at the Pathology Committee of the IASLC.

Dr. Anagnostou is the Alex Grass Professor of Oncology, co-director of the Upper Aerodigestive
Malignancies and the Cancer Genetics and Epigenetics Programs, leader of Precision Oncology
Analytics, co-leader of the Molecular Tumor Board, director of the Thoracic Oncology Biorepository and co-leader of the Thoracic Oncology Precision Medicine Center of Excellence in the Sidney Kimmel Cancer Center at Johns Hopkins. She graduated from Medical School of the National and Kapodistrian University of Athens, Greece and received a PhD from the same institution. After completing her internal medicine residency at Yale-New Haven Hospital, she subsequently trained in Medical Oncology at Johns Hopkins. Dr. Anagnostou is a translational cancer investigator, focusing on large-scale genomic and liquid biopsy analyses in human cancers. Her group has discovered novel genomic mechanisms of response and resistance to immunotherapy and her research is particularly focused on understanding the molecular mechanisms of response and resistance to these therapies, capturing these by minimally
invasive methods and translating this knowledge into novel technologies and innovative therapeutic approaches for cancer patients. She is the international study chair of the first ctDNA-based molecular response adaptive immuno-chemotherapy clinical trial for metastatic non-small cell lung cancer (NCT04093167). Her long term goal is to transform medical oncology to personalized molecular oncology, where treatment decisions are tailored to cancer genomics and molecular real-time response assessments informed by liquid biopsies.

Dr. Jordi Remon, MD, PhD is a medical oncologist with expertise in thoracic malignancies. Since 2022, he has been a full-time cancer specialist at Gustave Roussy (France) in the Medicine Department, where he focuses on treating patients with lung and thymic cancers.

His key interests include personalized therapeutic approaches for oncogene-addicted lung cancers, immunotherapy, and thymic malignancies. Dr. Remon is actively involved in multiple clinical trials and holds memberships in prestigious organizations such as ESMO, EORTC (serving as Chair of the Lung Cancer Group since May 2025), IASLC, and others.

Additionally, he serves as an editor for several leading oncology journals, including JCO, JTO, JTO CRR, and Lung Cancer.

Dr. Bruna Pellini is a board-certified thoracic medical oncologist and Chief of Thoracic Medical Oncology at Baptist Health Miami Cancer Institute in Miami, Florida, USA. Her clinical and research work focuses on integrating liquid biopsy technologies into the management of lung cancer, with particular emphasis on circulating tumor DNA for treatment response assessment, minimal residual disease detection and resistance profiling. She is an experienced clinical investigator who has developed and led investigator-initiated and multicenter clinical trials designed to translate biomarker science into meaningful improvements in patient care. 

Dr. Pellini has authored multiple peer-reviewed publications in high-impact journals, including the Journal of Clinical Oncology and Clinical Cancer Research, and has presented her work at major international meetings such as ASCO Annual Meeting, the International Association for the Study of Lung Cancer World Conference in Lung Cancer, and the International Society of Liquid Biopsy Annual Congress.  She currently serves as Translational Chair of the SWOG INSIGHT Phase III trial in early-stage non-small cell lung cancer and is the Co-Chair of the National Institutes of Health Liquid Biopsy Scientific Interest Group. 

In addition, Dr. Pellini serves on the editorial boards of JCO Oncology Advances and The Journal of Liquid Biopsy and participates in national guideline and scientific committees, including the ASCO Stage IV NSCLC Living Guidelines Panel and the ASCO Scientific Committee for Metastatic Non-Small Cell Lung Cancer. 

As incoming Co-Chair of the Education Committee for the International Society for Liquid Biopsy, she is committed to advancing global education, fostering multidisciplinary collaboration and accelerating the clinical implementation of liquid biopsy technologies worldwide. 

Luis E. Raez, MD, FASCO, FACP, FCCP works as Chief Scientific Officer & Medical Director of the Memorial Cancer Institute (MCI)/Memorial Health Care System, He is Co-Director of the MCI/FAU Florida Cancer Center of Excellence designated by the Florida Department of Health, one of only six cancer centers in Florida. He is also Director of the Thoracic Oncology Program. He is also Clinical Professor of Medicine at Florida International University (FIU), Visiting Professor of Medicine at Cayetano Heredia University in Peru and Research Professor at Florida Atlantic University (FAU). He was the Vice-President of the Florida Society of Clinical Oncology (FLASCO) 2017-19 and President 2019-2021.

He was an Associate Professor of Medicine, Epidemiology and Public Health, and a Co-Director of Thoracic Oncology at Sylvester Cancer Center/University of Miami for 10 years (2001-2011). He has expertise in medical oncology in the area of lung cancer, cancer disparities and liquid biopsies,
He designs phase I-III clinical trials with new targeted agents and immunotherapy. Dr. Raez does translational research and clinical research. He has been funded by NCI and the pharma industry. He has given oral presentations and lectures in national and international meetings in the US, Europe, Latin-America, Africa and Asia.

He has been the Chairman of the IASLC Latin American Group (LATAM) since 2018; Chair of the IASLC Membership Committee from 2015-2018; International Chair of the IASLC-Latin-American Meeting (LALCA) since 2014; Chairman for the “Miami Best of ASCO” since 2014, Chair and Founder of the “Miami Cancer Meeting (MCM)” since 2002, Co-Chairman at the “Puerto Rico Fall Cancer Symposia (FCS)” since 2010. He is one of the founder members of Oncology Latin-American Association (OLA).

He is American Board Certified in: Internal Medicine and Medical Oncology. He is board eligible in Hematology.
He is a member and serves in several committees at: AACR, OLA, ESMO, ASCO, IASLC, ALLIANCE, NCCTG, ACCP, ACP, ACSG, SLACOM, FLASCO among other institutions.